SCREENING OF PCSK9 RELATIVE AGENT OR MEASUREMENT METHOD OF PCSK9 TO ASCERTAIN ADMINISTRATION EFFECT OF AGENT

摘要

PROBLEM TO BE SOLVED: To investigate a behavior of PCSK9 in vivo and provide means to gain a better insight into the nature and to contribute to the advancement of diagnosis/medical areas.SOLUTION: In a test system of a test drug which decomposes PCSK9 heterodimer into a pro-segment and a 60 kDa segment (non-heterodimer) by clarifying that a PCSK9 segment of the 60 kDa (60 kDa segment (non-heterodimer)) exists in blood in a non-heterodimer state, a measurement method for determining a ratio of the 60 kDa segment (non-heterodimer) before use and after use of the agent to the PCSK9 heterodimer or the whole PCSK9 is provided, and for example, the PCSK9 heterodimer in blood is subjected to a non-heterodimer, thereby enabling screening of the agent which reduces LDL cholesterol in blood.